People · Operator
Named in public records as an officer, director or promoter · active 2005–2018 · Biotech / Pharma, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akoya Biosciences, Inc. | — | Biotech / Pharma | Series B | $33.5M | $901.1M | 2017 |
| Aquaro Histology, Inc. | — | Biotechnology | Series A | $9.8M | $354.7M | 2017 |
| Ldr Holding Corp | — | Other Technology | Series A | $9.7M | $269.7M | 2012 |
| BioProtection Systems Corp | — | Biotechnology | Seed | $4.0M | $5.5M | 2005 |
Thomas Raffin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Thomas Raffin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Rob Hart | 2 | 5 |
| Robert Shepler | 2 | 4 |
| Jack Ball | 1 | 10 |
| Kevin Lalande | 1 | 8 |
| DEVAL LASHKARI | 1 | 6 |
| Matthew Winkler | 1 | 3 |
| Charles Link | 1 | 3 |
| STEVE STAHLY | 1 | 2 |
| Stefan Widensohler | 1 | 2 |
| Robert E. McNamara | 1 | 2 |
| Garry Nolan | 1 | 2 |
| Joseph Lucas | 1 | 1 |
| Carl Langren | 1 | 1 |
| Nick Vahanian | 1 | 1 |
| Brian McKelligon | 1 | 1 |
| Alberto Elli | 1 | 1 |
| Scott E. Way | 1 | 1 |
| Matt Crawford | 1 | 1 |
| Pierre Remy | 1 | 1 |
| Joseph Aragona | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.